摘要
目的分析2型糖尿病合并骨质疏松症患者的骨密度情况。方法选取2020年7月—2021年3月期间本院收治的52例2型糖尿病合并骨质疏松症患者作为观察组,另选择同期在本院体检的52例单纯骨质疏松症患者作为对照组。观察两组患者骨密度改变,并监测血浆同型半胱氨酸、骨代谢相关指标变化。结果观察组骨密度值(0.72±0.35)g/cm^(2)显著低于对照组(0.78±0.19)g/cm^(2),差异有统计学意义(P<0.05)。观察组血浆同型半胱氨酸(18.69±4.16)μmol/L、碱性磷酸酶(116.28±19.67)U/L显著高于对照组(8.59±5.02)μmol/L、(79.25±25.03)U/L,差异有统计学意义(P<0.05)。严重骨质疏松组骨密度值、血浆同型半胱氨酸、血钙、碱性磷酸酶、血清25-维生素D水平与骨质疏松组比较,差异有统计学意义(P<0.05)。结论2型糖尿病合并骨质疏松症患者存在明显骨密度下降问题,且合并骨代谢异常,应积极采取对应干预措施,控制骨质疏松症进展。
Objective To analyze the bone mineral density of patients with type 2 diabetes mellitus complicated with osteoporosis.Methods From July 2020 to March 2021,52 patients with type 2 diabetes and osteoporosis were selected as the observation group.52 patients with osteoporosis were selected as control group.The changes of bone mineral density,plasma homocysteine and bone metabolism were observed.Results The BMD of the observation group(0.72±0.35)g/cm^(2) was significantly lower than that of the control group(0.78±0.19)g/cm^(2),the difference was statistically significant(P<0.05).The plasma homocysteine(18.69±4.16)μmol/L and alkaline phosphatase(116.28±19.67)U/L in the observation group were significantly higher than those in the control group(8.59±5.02)μmol/L,(79.25±25.03)U/L,the difference was statistically significant(P<0.05).There were significant differences in bone mineral density,plasma homocysteine,serum calcium,alkaline phosphatase and serum 25 vitamin D between severe osteoporosis group and osteoporosis group(P<0.05).Conclusion The patients with type 2 diabetes mellitus complicated with osteoporosis have obvious bone mineral density decline and abnormal bone metabolism,so corresponding intervention measures should be actively taken to control the progress of osteoporosis.
作者
张杨
ZHANG Yang(Department of Endocrinology,The Second People's Hospital of Guiyang,Guiyang Guizhou 550081,China)
出处
《中国卫生标准管理》
2022年第12期76-79,共4页
China Health Standard Management
关键词
2型糖尿病
合并
骨质疏松症
骨密度
骨代谢
血浆同型半胱氨酸
type 2 diabetes mellitus
merger
osteoporosis
bone mineral density
bone metabolism
plasma homocysteine